TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Postoperative Pain Score on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3D measure of postoperative swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faecal incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration Curve From Zero to Infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimum tolerated regimen (OTR)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in lab values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Quality of Recovery-15 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Difference in stiffness between nerves and surrounding tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depth of small intestine advancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visualization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Epicardial fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Steady-state Plasma Glucose (SSPG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Secretion Rate Area Under the Curve (ISR-AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of sillicium in urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS4)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change of local cerebral oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Any Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Visceral adipose fat change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intrahepatic lipid stores change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inception and progression of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pain in the mastectomy area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Incidence of Mycobacterium Tuberculosis Infection
Endpoint domain: Mortality/survival
Primary endpoint: steady-state pharmacokinetics of escitalopram
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC (0-tlast) of BAY1093884 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of BAY1093884 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Altitude related adverse health effects (ARAHE), cumulative incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Fecal Incontinence and Constipation Assessment (FICA) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ocular safety assessed by BCVA, slitlamp examination, ophthalmoscopy, IOP, fundus photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Laboratory Test Values of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Vital Signs Findings of Potential Clinical Importance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Competence of operating room nurses
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Patients That Achieve Stable Disease or Clinical Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experienced Dose-Limiting (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in % predicted FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in % predicted DLCO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Hamilton Rating Scale for Depression (HRSD) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Expectant Mothers Experiencing Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Expectant Mothers Experiencing Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Take-Home Baby Rate
Endpoint domain: Mortality/survival
Primary endpoint: Fugl-Meyer Assessment Upper Extremity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-Free Survival (PFS) at Month 4
Endpoint domain: Mortality/survival
Primary endpoint: Cumulative incidence of Mortality at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Change in CAC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to onset-of-action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerance to existing allergen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of diabetic foot ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Breast cosmesis grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of EBUS-TBNA vs. mediastinoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physiological status change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in visual features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in audio features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of abnormal epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CRLX101 (CPT) Uptake in Tumor and Nearby Normal Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of adverse events related to R-EPOCH
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events related to lentivirus vector infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Hemoglobin status (positive or negative for A, S, or C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Average FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Whole Brain Total Distribution Volume (VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Uptake Value (SUV) Area Under the Curve (AUC) (60-120min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Financial costs of stimulation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Classification accuracy of motor events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mean CSF BCL11b levels at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Level of 1H-MRS Myo-Inositol in Frontal White Matter at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean CSF HIV RNA by Single Copy Assay at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean CSF HIV tat at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean CSF neopterin at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Markers of bone remodeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Message Effectiveness Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Affective Improvement Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of women willing to be randomised
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diaphragmatic excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum tolerated dose (MTD) of LNA-i-miR-221
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recommended phase II dose of LNA-i-miR-221 (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Best Corrected Visual Acuity (BCVA) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUGtau) of Ethinyl Estradiol (EE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUGtau) of Levonorgestrel (LN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile (AUCinf) of PF-06826647
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of PF-06826647
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grip or pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time return to work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Transfusion requirements following surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes in reticulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intraocular Pressure Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes in TSPO Radiotracer Uptake Infarct Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in TSPO Radiotracer Uptake Distant Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Dose Limiting Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area Under Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of Paired Patients With Ventricular Arrhythmia (VA) Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of Paired Patients Who Experienced at Least One ICD or CRT-D Shock and ATP Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of rectum preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Hyperglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Days to Remission of Depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Morphologic Complete Remission (CR) at the End of Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Composite Complete Remission at the End of Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Participants With Overall Response at the End of Induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Subjects With Any and Grade 3 Solicited Local Symptoms After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3 and Related Medically-attended Adverse Events (MAEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any and Related Serious Adverse Events (SAEs) After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Anxiety (STAI score)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in Total Tics on the YGTSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle wasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until partus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in Voluntary Cough Peak Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Particle size distribution of masticated nuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the ROC curve for total power Doppler score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival at discharge
Endpoint domain: Mortality/survival
Primary endpoint: Number of Treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Measurement of HBsAg decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in DNA methylation patterns in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in neuroinflammatory and neuropeptide patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in plasma levels of Neurofilament light protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in interleukin 6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Headache Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Pain Ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Completed at Least Half of Their High Intensity Interval Training Sessions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total time taken to complete the ESD procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Difference in systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in plasma renin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Overall Response (CR + CRh + CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cue-induced nicotine craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Symptoms and Medication Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin infection
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Muscle activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Ankle dorsiflexion ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Changes in Dynamic Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time first pass flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in inspiratory muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: free alpha subunit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Visual analogic scale of appetite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand grip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: student stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worry levels as measured by the Penn State Worry Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain measurement using Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Acne Lesion Counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Improvement Scale (CGI)-Improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of candidate target expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Precision of predictive early warning score algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: wall/lumen ratio (WLR) of retinal arterioles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Heavy Drinking Days
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of Patients That Achieved Target Suramin Concentrations in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Response Rate (Complete Response and Partial Response) as Measured by RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low Prolaris Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome of infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Additional serrated lesions diagnosed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Gene Expression Change of CD34+ Endothelial Progenitor Cells (Protein Expression)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function Change of CD34+ Endothelial Progenitor Cells (Cell Percentages)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function Change of CD34+ Endothelial Progenitor Cells (Cell Counts)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function Change of CD34+ Endothelial Progenitor Cells (Cell Proliferation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fetal cardiac dysfunction diagnosis and prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Foot intrinsic muscle strength with the make test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Foot intrinsic muscle strength with the break test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: axial diffusivity (AxD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: radial diffusivity (RD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: patient diary compliance
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Global evaluation of efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Crossover stress (mucus rheology)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disabilities of Arm, Shoulder & Hand (DASH) questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SF-36 patient survey scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pinch/grip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hydrocarbonated metabolism parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Estimated Blood Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Volume of transfused packed red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in Carotid-femoral Pulse Wave Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flux of citrulline and nitrate through the urea cycle pathway
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total plasma arginine flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes